HIV Drug Developments: From Daily Pills to Twice-Yearly Shots — a Market in Motion

The HIV treatment market is undergoing one of its most consequential shifts in decades. Where once the debate centered on tolerability and pill burden, the battleground now is dosing frequency, real-world delivery and global access. Long-acting agents — most visibly lenacapavir, a capsid inhibitor that can be given as a twice-yearly injection — have moved from promising science to regulatory reality and national rollout planning, forcing payers, ministries of health and manufacturers to confront supply, price and distribution questions that will determine whether clinical benefit translates into population-level impact.

Who’s Leading the Race — The Usual Suspects and New Challengers

Big pharma still sets the tempo. Gilead Sciences (NASDAQ: GILD), whose portfolio already dominates modern ART (antiretroviral therapy), has pivoted hard into long-acting prevention with lenacapavir and is coordinating regulatory filings and supply partnerships across sub-Saharan Africa. ViiV Healthcare, a specialist HIV company backed by GSK and others, remains the standard-bearer for long-acting injectables in both treatment and PrEP (pre-exposure prophylaxis) with products such as Cabenuva and investigational broad-spectrum antibodies. Merck, Janssen (Johnson & Johnson), AbbVie and Roche continue to invest in next-generation ARVs, entry inhibitors and long-acting formats, while generics groups and established Indian producers (eg. Cipla) remain important players for affordability and bulk supply. Small and mid-size biotechs — makers of broadly neutralizing antibodies (bnAbs), novel capsid inhibitors and mRNA vaccine platforms — are providing the scientific diversification the field needs.

The Science: Prevention Advances, Cure Signals and Vaccine Momentum

The clearest near-term advance is prevention. Injectable lenacapavir cleared major regulatory hurdles and has drawn WHO endorsement for use as long-acting PrEP — a potential game changer in settings where daily adherence is a challenge. Simultaneously, combination approaches that pair bnAbs with immune stimulants are reporting encouraging signals in early trials, suggesting longer periods of drug-free viral control may be achievable in a subset of patients. On the vaccine front, 2025 has delivered notable proof-of-concept data: mRNA-based immunogens and sequential immunization strategies have triggered neutralizing antibody pathways previously considered extremely hard to reach — turning what was theoretical into actionable trial programs. Those strands — long-acting prevention, bnAb-led remission strategies and mRNA vaccine platforms — are converging into a multi-pronged assault on HIV. 

Here, the IAVI G002 and G003 phase 1 trials, conducted across North America, South Africa, and Rwanda, showed that a stepwise, germline-targeting approach using mRNA-encoded nanoparticles can reliably activate and advance bnAb precursors — in other words, they successfully “kick-start” the immune system to target HIV in a way that was previously very difficult. In G002, a heterologous prime-boost regimen triggered VRC01-class responses in all boosted participants, with over 80% achieving “elite” maturation profiles — meaning most participants’ immune systems developed antibodies with strong potential to block many HIV variants. G003 confirmed strong priming responses in African participants, demonstrating that the strategy is effective in high-burden populations — showing that this approach could actually work where HIV is most prevalent.

Published in Science and supported by the Gates Foundation, NIH, USAID, and Moderna, these results move bnAb-based vaccination from concept to actionable development program, highlighting a practical pathway for global HIV vaccine deployment — in simple terms, this is a major step toward a real-world HIV vaccine that could be used worldwide.

Market, Manufacturing and Pricing — The Implementation Problem

If the science is advancing, the economics remain a Gordian knot. Early pricing for long-acting injectables is orders of magnitude higher in wealthy markets than what low- and middle-income countries can afford; analysts and activists point to the gap between list prices and feasible public-health prices as the main bottleneck to rapid scale up. Manufacturing capacity for sterile injectables, cold-chain logistics and trained clinic staff to deliver twice-yearly injections are concrete constraints in high-burden regions. Voluntary licensing and technology transfer could blunt these issues, but negotiations over royalties, local production and quality standards will control who gets access first and how fast. 

These challenges are already visible in real-world rollout efforts. Gilead has begun delivering twice-yearly lenacapavir to Sub-Saharan Africa, with South Africa registering the drug and planning distribution in early 2026, while Kenya, Eswatini, and Zambia are set to follow. Despite this progress, the price gap remains stark: annual list prices exceed $28,000 in the U.S., far beyond the budgets of public-health programs in low- and middle-income countries. Logistics add further constraints — each injection requires cold-chain storage, trained staff, and an initial oral lead-in, limiting how quickly the drug can reach high-risk populations. Advocacy groups like AVAC note that voluntary licensing and access agreements can speed distribution, but negotiations over royalties, local production, and quality standards will ultimately determine which communities benefit first. In short, the science has advanced faster than the systems that deliver it.

Politics and Funding: A Fragile Backdrop

Politics is shaping the rollout almost as much as science. Recent U.S. policy shifts under the Trump administration — involving pauses or re-scoping of certain bilateral health aid lines and tensions in diplomatic channels — have put established funding streams and implementation partnerships under strain, reigniting concerns that donor retrenchment will slow national programs in Africa just as new tools become available. South Africa — one of the countries with the largest HIV burdens and the most to gain from long-acting PrEP — has found itself at the center of that confrontation, complicating procurement and donor coordination. The upshot: scientific breakthroughs may be necessary but not sufficient; durable financing and geopolitics will determine who benefits.

Resistance, Equity and the Road to a Cure

Two structural scientific challenges persist. First, the viral reservoir — dormant HIV integrated into host DNA — remains the chief biological barrier to a sterilizing cure. Cure research is progressing through “kick-and-kill” and immune-modulating strategies, and a handful of trials report delayed rebound under combination bnAb/immune-stimulant regimens. But translating remission signals into scalable, affordable interventions remains a long-term bet. Second, equity issues — from stigma to the uneven reach of clinic systems — mean that any high-tech advance risks widening gaps unless deliberately paired with access policies and strong community engagement.

The field stands at an inflection point: therapeutic innovation is arriving precisely when implementation systems and global financing are under pressure. That paradox will be the defining story of HIV in the next five years — not whether the science can deliver, but whether policy, price and politics will allow it to reach the people who need it most.

Author

Bernice Lottering